WINT Stock Overview
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases.
Windtree Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.32|
|52 Week High||US$2.37|
|52 Week Low||US$0.28|
|1 Month Change||-21.32%|
|3 Month Change||-23.19%|
|1 Year Change||-83.99%|
|3 Year Change||-97.15%|
|5 Year Change||-97.29%|
|Change since IPO||-100.00%|
Recent News & Updates
|WINT||US Biotechs||US Market|
Return vs Industry: WINT underperformed the US Biotechs industry which returned -27.4% over the past year.
Return vs Market: WINT underperformed the US Market which returned -22.1% over the past year.
|WINT Average Weekly Movement||19.8%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: WINT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: WINT's weekly volatility has increased from 13% to 20% over the past year.
About the Company
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company’s lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program.
Windtree Therapeutics, Inc. Fundamentals Summary
|WINT fundamental statistics|
Is WINT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|WINT income statement (TTM)|
|Cost of Revenue||US$17.79m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.53|
|Net Profit Margin||0.00%|
How did WINT perform over the long term?See historical performance and comparison